Gene Expression Profiles Distinguish Idiopathic Pulmonary Fibrosis from Hypersensitivity Pneumonitis

Many of the interstitial lung diseases represent a diagnostic and therapeutic challenge because their clinical and even histologic features are often nonspecific. Likewise, the transcriptional signatures of most of them are unknown. To compare the gene expression patterns from patients with idiopath...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of respiratory and critical care medicine Vol. 173; no. 2; pp. 188 - 198
Main Authors Selman, Moises, Pardo, Annie, Barrera, Lourdes, Estrada, Andrea, Watson, Susan R, Wilson, Keith, Aziz, Natasha, Kaminski, Naftali, Zlotnik, Albert
Format Journal Article
LanguageEnglish
Published New York, NY Am Thoracic Soc 15.01.2006
American Lung Association
American Thoracic Society
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Many of the interstitial lung diseases represent a diagnostic and therapeutic challenge because their clinical and even histologic features are often nonspecific. Likewise, the transcriptional signatures of most of them are unknown. To compare the gene expression patterns from patients with idiopathic pulmonary fibrosis (IPF) hypersensitivity pneumonitis (HP), and nonspecific interstitial pneumonia (NSIP) using custom oligonucleotide microarrays. We profiled lung biopsies from 15 patients with IPF, 12 with HP, and eight with NSIP. Labeled complementary ribonucleic acid was hybridized to a custom Affymetrix oligonucleotide DNA microarray using standard Affymetrix protocols. The custom array, Hu03, contained 59,619 probe sets representing an estimated 46,000 gene clusters. We identified statistically significant gene expression signatures that characterize HP and IPF. The HP gene expression signature was enriched for genes that are functionally associated with inflammation, T-cell activation, and immune responses, whereas the IPF signature was characterized by the expression of tissue remodeling, epithelial, and myofibroblast genes. We then compared these gene expression signatures to classify NSIP, a histologic pattern that is often difficult to differentiate consistently from HP and IPF. Two cases exhibited an IPF-like gene expression, another one could be more properly classified as HP, whereas others did not resemble HP or IPF, suggesting that they may represent idiopathic NSIP. Our results underscore the value of gene expression signatures to classify the interstitial lung diseases and to understand pathogenic mechanisms, and suggest new ways to improve the diagnosis and treatment of patients with these diseases.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
These authors contributed equally to this study.
Correspondence and requests for reprints should be addressed to Albert Zlotnik, Ph.D., Neurocrine Biosciences, 12790 El Camino Real, San Diego, CA 92130. E-mail: azlotnik@neurocrine.com
Conflict of Interest Statement: M.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.P. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. L.B. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.E. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.R.W. was an employee of Eos Biotechnology from November 1998–February 2003. She has filed patents on the lung fibrosis microarray data, and owns shares in Protein Design Labs. K.W. is currently employed by and has stock and stock options in Protein Design Labs, which is the parent company of Eos Biotechnology, an original sponsor of the research. N.A. was an employee of Eos Biotechnology from January 2000–March 2003. She has filed patents on the lung fibrosis microarray data, and owns shares in Protein Design Labs. N.K. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.Z. was an employee of Eos Biotechnology from September 2000–March 2003. He owns shares in Protein Design Labs, a company that acquired Eos Biotechnology. A provisional patent application was filed by Eos Biotechnology on some data contained in this article. He is currently employed by Neurocrine Biosciences, which has no financial interests in the contents of this article.
This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org
Originally Published in Press as DOI: 10.1164/rccm.200504-644OC on September 15, 2005
Supported in part by National Institutes of Health grant HL 073745-01, and by a generous donation from the Simmons family (N.K.), and by DGAPA, UNAM IN215003 (A.P.).
ISSN:1073-449X
1535-4970
DOI:10.1164/rccm.200504-644OC